Indiana Clinical Trials Report — June 2026

For Hoosiers considering participation in clinical research this June, a significant number of trials are nearing their enrollment deadlines, creating a time-sensitive opportunity. Across Indiana, 81 clinical trials are slated to close within the next 90 days. Among these, 19 studies are actively seeking healthy volunteers, offering a chance to contribute to medical advancements without needing a specific health condition. If you've been thinking about participating, now is a crucial time to explore these options before they conclude.

Individuals living with certain health conditions should also act quickly to review trials with impending deadlines. Research focusing on conditions like cystic fibrosis and advanced solid tumors are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cystic fibrosis (CF)
• Advanced solid tumor
• Pain
• Acute liver injury
• Adult thoracic procedures
• Adult urological procedures
• Adult surgical procedures
• Alcohol use disorder
• Alzheimer's disease

New Horizons in Indiana Research: Obesity, Diabetes, and More

This June, Indiana welcomes 21 new clinical trials, offering fresh opportunities for participation across the state. While this is a slight decrease from the 28 trials that opened in May 2026, the new studies include several significant Phase 2 and Phase 3 drug trials from major pharmaceutical companies, alongside important academic initiatives. These trials are exploring cutting-edge treatments for widespread health challenges like obesity and type 1 and type 2 diabetes.

Notable new trials opening this month include:

• AstraZeneca is sponsoring NCT07667803, a global Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial for weight loss, NCT07668414, is sponsored by Novo Nordisk A/S. This study is "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide," seeking 650 participants.
• For those with type 2 diabetes, Novo Nordisk A/S is also leading NCT07668388, a Phase 2 study titled "A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes." This trial aims to enroll 300 participants to assess the efficacy and safety of UBT251.
• Indiana University is sponsoring NCT07640139, an observational study titled "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes." This large-scale initiative plans for 125,000 participants to understand the real-world impact of incretin-based obesity medications.
• Also from Indiana University, NCT07663136, "Finding Immune Nascent Type 1 Diabetes," is an important study aiming for 3,800 participants. It seeks to understand the most effective ways to recruit individuals for type 1 diabetes home screening.
• Vanderbilt University Medical Center is sponsoring NCT07674758, an observational study on "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This study plans to enroll 1,000 participants to better understand heart dysfunction in Duchenne and Becker Muscular Dystrophy.
• Purdue University is leading NCT07620028, "Improving Dietary Quality Through Animal Source Protein Accessibility in a Low-Resource Setting," an observational study with 500 participants focusing on adolescent nutrition.
• Claris Biotherapeutics, Inc. is sponsoring NCT07636590, a "Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency," which aims to enroll 500 participants to describe the natural history and management of this eye condition.

The 21 new trials cover a diverse range of health conditions, with a strong emphasis on metabolic health. The most common conditions addressed by these new studies include:

• Obesity (3 trials)
• Type 1 diabetes (2 trials)
• Becker muscular dystrophy (1 trial)
• Carrier of Duchenne muscular dystrophy (1 trial)
• CFTR gene mutation (1 trial)
• Chronic kidney disease, 3b and 4 (1 trial)
• Diabetes mellitus, type 2 (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 8 of the new studies. Behavioral interventions and device trials are also well-represented, each with 4 new trials.

Research Opportunities Across Indiana: A Focus on Central Hubs

Indiana's clinical research landscape remains active, with 1,198 clinical trials currently recruiting across 60 cities and 746 research sites statewide. This month, the majority of new research initiatives are concentrated in central Indiana, particularly within the Indianapolis metropolitan area, which saw 18 new trials open. However, opportunities are also expanding in other parts of the state:

• Indianapolis (18 new trials)
• Bloomington (2 new trials)
• Carmel (1 new trial)
• Ellettsville (1 new trial)
• Muncie (1 new trial)

This distribution highlights the accessibility of cutting-edge research for residents in various regions, with Indianapolis continuing to serve as a primary hub for clinical investigations.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 21 new trials launched this month, 5 are actively seeking healthy volunteers. Statewide, a total of 127 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing health knowledge.

Clinical trials in Indiana are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 6 include children as participants, and 16 include older adults, ensuring that research benefits diverse age groups. Academic institutions continue to play a vital role in the state's research ecosystem, with Indiana University sponsoring 7 of the new trials, and Purdue University and Ball State University also contributing. Industry sponsors are driving significant research efforts, with 7 new trials sponsored by pharmaceutical companies such as Novo Nordisk A/S, AstraZeneca, and Claris Biotherapeutics, Inc. Additionally, the VA Office of Research and Development is sponsoring 3 new trials, reflecting a commitment to veteran health.

As we move through June, the focus will remain on the ongoing enrollment in these significant trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Indiana.